The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Aglaia BioMedical Ventures; Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen-Cilag; MSD
Speakers' Bureau - Bristol-Myers Squibb; MSD
Research Funding - Astellas Pharma; Bayer; Janssen-Cilag
Travel, Accommodations, Expenses - Amgen; Bayer
Association of concomitant use of acid reducing agents in full-dose vemurafenib users with risk of progression in BRAF V600 mutation-positive unresectable or metastatic melanoma patients: A retrospective cohort study.
 
Lotte Marieke Knapen
No Relationships to Disclose
 
Rutger H.T. Koornstra
Consulting or Advisory Role - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst); Viper (Inst)
 
Johanna H.M. Driessen
No Relationships to Disclose
 
Bas Van Vlijmen
No Relationships to Disclose
 
Sander Croes
No Relationships to Disclose
 
Stein J. Schalkwijk
No Relationships to Disclose
 
Angela Colbers
Research Funding - Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); Janssen (Inst); Merck (Inst); ViiV Healthcare (Inst)
 
Winald Gerritsen
No Relationships to Disclose
 
David Burger
No Relationships to Disclose
 
Frank de Vries
No Relationships to Disclose
 
Nielka P. Van Erp
Speakers' Bureau - Sanofi
Research Funding - Amgen (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Janssen-Cilag (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)